Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NIOX GroupCSSPF 77 Revenue per Share is $0.15 as of Dec. 2025. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 754 Medical Devices & Instruments companies, NIOX Group ranks better than 80.24% on this metric.
NIOX Group's revenue per share for the
six
months ended in Dec. 2025 was $0.07.
NIOX Group's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.
During the past 12 months, the average Revenue Per Share Growth Rate of NIOX Group was 22.60% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 17.10% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 12.90% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 1.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for NIOX Group's Revenue per Share or its related term are showing as below:
CSSPF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -24.3 Med: 6.95 Max: 48.2
Current: 17.1
During the past 13 years, NIOX Group's highest 3-Year average Revenue Per Share Growth Rate was 48.20% per year. The lowest was -24.30% per year. And the median was 6.95% per year.
CSSPF's 3-Year Revenue Growth Rate is ranked better than 80.24% of 754
companies
in the Medical Devices & Instruments industry
Industry Median: 3.8
vs CSSPF: 17.10
NIOX Group (OTCPK:CSSPF) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
NIOX Group Revenue per Share Related Terms
NIOX Group Revenue per Share Historical Data
* Premium members only.
The historical data trend for NIOX Group's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSSPF vs ABT, SYK, MDT: Revenue per Share Comparison
For the Medical Devices subindustry, NIOX Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where NIOX Group's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
NIOX Group's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a Revenue per Share of $0.15 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #149 out of 754 companies in the Medical Devices & Instruments industry, placing it in the top 19.8%.
Is NIOX Group's Revenue per Share too high?
NIOX Group's current Revenue per Share is $0.15. The Medical Devices & Instruments industry median Revenue per Share is 3.80. NIOX Group's value of $0.15 is 96.1% below this industry median. Based on the distribution chart, NIOX Group ranks #149 out of 754 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Revenue per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #149 out of 754 companies for Revenue per Share. This places NIOX Group in the top 20% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.80. NIOX Group's value of $0.15 is 96.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.80, based on 754 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Revenue per Share of $0.15 is 96.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Revenue per Share is $0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current Revenue per Share is $0.15 and 96.1% below the Medical Devices & Instruments industry median of 3.80. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Revenue per Share is $0.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Revenue per Share: $0.15
GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
Industry Position: 96.1% below the Medical Devices & Instruments median (#149 of 754)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
